Phase 1 Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas

Trial Profile

Phase 1 Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 28 Dec 2017

At a glance

  • Drugs Belinostat (Primary) ; Volasertib (Primary)
  • Indications B cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Dec 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 13 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top